Capital Guardian Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital Guardian Trust’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$27.3M	Sell	430,627 -40,220	-9%	-$2.56M	0.37%	102
2019 Q1	$32.7M	Buy	470,847 +9,995	+2%	+$571K	0.43%	90
2018 Q4	$20M	Sell	460,852 -7,779	-2%	-$425K	0.32%	102
2018 Q3	$35.8M	Buy	468,631 +7,983	+2%	+$649K	0.48%	80
2018 Q2	$35.4M	Sell	460,648 -35,245	-7%	-$2.28M	0.5%	81
2018 Q1	$25.3M	Sell	495,893 -20,220	-4%	-$1.02M	0.36%	98
2017 Q4	$23.9M	Sell	516,113 -4,922	-0.9%	-$241K	0.34%	105
2017 Q3	$27.8M	Buy	521,035 +8,605	+2%	+$510K	0.48%	80
2017 Q2	$31.8M	Sell	512,430 -111,744	-18%	-$6.73M	0.58%	68
2017 Q1	$42.3M	Buy	624,174 +53,853	+9%	+$4.1M	0.32%	109
2016 Q4	$40.1M	Buy	570,321 +77,421	+16%	+$5.49M	0.31%	106
2016 Q3	$35M	Buy	+492,900	New	+$31.5M	0.26%	116

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital Guardian Trust's RARE Position: Q2 2019 in Review

Capital Guardian Trust reduced its Ultragenyx Pharmaceutical (RARE) stake by 8.5% in Q2 2019, selling an estimated $2.56M and leaving 430,627 shares worth $27.3M. The position accounts for 0.37% of the portfolio, ranked #102.

Capital Guardian Trust first reported a position in RARE in Q3 2016 and has held it in 12 quarters since. The position peaked at $42.3M in Q1 2017. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

Capital Guardian Trust held 430,627 shares of Ultragenyx Pharmaceutical worth $27.3M as of Q2 2019.
Capital Guardian Trust sold 40,220 Ultragenyx Pharmaceutical shares in Q2 2019, an estimated $2.56M.
Ultragenyx Pharmaceutical made up 0.37% of Capital Guardian Trust's portfolio in Q2 2019, its #102 holding.
Capital Guardian Trust first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and has held it in 12 quarters since.
Capital Guardian Trust's Ultragenyx Pharmaceutical position peaked at $42.3M in Q1 2017.
170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on Capital Guardian Trust's 13F filing for Q2 2019, filed 14 Aug 2019.